Nanda V, Gupta V, Sharma S N, Pasricha A, Karmakar A Kumar, Patel A, Bhatt V M, Kantroo B L, Kumar B, Paul N K Ketar, Attam R
Kidney Hospital and Lifeline Medical Institutions, Punjab, India -
Minerva Med. 2014 Dec;105(6 Suppl 2):1-8.
Liverubin™ is an available drug in the Indian market that contains silymarin, the major active complex extracted from the medicinal plant milk thistle (Silybum marianum L.). The study retrospectively tracked and analyzed the data of 602 patients, out of which 230 were alcohol induced; 131 with alcohol-induced liver damage (ALD), 13 with liver cirrhosis, and 86 with fatty liver; to assess the effects of water soluble Silymarin (Liverubin™) on important hepatic biochemical parameters. The data was collected from 32 major cities treated by 72 physicians across India who were observed for the specified treatment duration of 11 months. Data was analyzed by using descriptive statistics. At the end of the treatment the hepatic biochemical profile was appreciably improved: the mean % of change in the levels of important hepatic biochemical parameters was observed as follows: total bilirubin 63.48% (direct bilirubin: 64.96%; indirect bilirubin: 61.63%). The serum SGOT and SGPT changed at a mean % of 65.43 and 69.31 respectively while serum alkaline phosphatase was changed at a mean % rate of 39.81. Liverubin™ proved to be safe & well-tolerated among the studied population and no significant treatment related adverse events were reported during the study. Liverubin™ treatment is found to bring about effective lowering of abnormally elevated hepatic biochemical parameters. Liverubin™, water soluble active Silymarin, in the popularly prescribed doses of 140-mg tid is observed to be a promising safe and effective drug in cases of alcoholic liver disease.
利肝红素™是印度市场上一种现有的药物，其含有水飞蓟宾，这是从药用植物水飞蓟（水飞蓟属植物）中提取的主要活性复合物。该研究回顾性地跟踪和分析了602名患者的数据，其中230名是酒精诱导的；131名患有酒精性肝损伤（ALD），13名患有肝硬化，86名患有脂肪肝；以评估水溶性水飞蓟宾（利肝红素™）对重要肝脏生化参数的影响。数据收集自印度各地72名医生治疗的32个主要城市，观察期为指定的11个月治疗时长。数据采用描述性统计进行分析。治疗结束时，肝脏生化指标明显改善：重要肝脏生化参数水平的平均变化百分比如下：总胆红素63.48%（直接胆红素：64.96%；间接胆红素：61.63%）。血清谷草转氨酶（SGOT）和谷丙转氨酶（SGPT）的平均变化百分比分别为65.43和69.31，而血清碱性磷酸酶的平均变化率为39.81。在研究人群中，利肝红素™被证明是安全且耐受性良好的，研究期间未报告与治疗相关的重大不良事件。发现利肝红素™治疗可有效降低异常升高的肝脏生化参数。利肝红素™，即水溶性活性水飞蓟宾，常用剂量为每日三次，每次140毫克，在酒精性肝病病例中被认为是一种有前景的安全有效药物。
